Get the Stockscreener App
17.98
3.51%
0.61
Denali Therapeutics Inc stock is traded at $17.98, with a volume of 1.35M.
It is up +3.51% in the last 24 hours and up +2.63% over the past month.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
See More
Previous Close:
$17.37
Open:
$17.41
24h Volume:
1.35M
Relative Volume:
0.76
Market Cap:
$2.64B
Revenue:
$340.81M
Net Income/Loss:
$-419.65M
P/E Ratio:
-6.3088
EPS:
-2.85
Net Cash Flow:
$-402.10M
1W Performance:
-9.92%
1M Performance:
+2.63%
6M Performance:
+20.47%
1Y Performance:
-23.39%
1-Day Range:
$17.24
$18.30
1-Week Range:
$17.20
$20.57
52-Week Range:
$10.57
$24.34
Denali Therapeutics Inc Stock (DNLI) Company Profile
Name
Denali Therapeutics Inc
Sector
Industry
Phone
(650) 866-8547
Address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
17.98 | 2.55B | 340.81M | -419.65M | -402.10M | -2.85 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-07-25 | Resumed | Morgan Stanley | Overweight |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Jan-07-25 | Initiated | Robert W. Baird | Outperform |
| Jan-03-25 | Initiated | William Blair | Outperform |
| Dec-16-24 | Upgrade | Stifel | Hold → Buy |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Oct-07-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-23 | Initiated | B. Riley Securities | Buy |
| Jan-30-23 | Initiated | SVB Securities | Outperform |
| Dec-05-22 | Initiated | Cowen | Outperform |
| Nov-02-22 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-02-22 | Initiated | BofA Securities | Buy |
| Jun-23-22 | Initiated | Berenberg | Buy |
| Dec-10-21 | Resumed | Raymond James | Mkt Perform |
| Sep-21-21 | Initiated | Oppenheimer | Outperform |
| Sep-01-21 | Initiated | SMBC Nikko | Outperform |
| May-18-21 | Initiated | UBS | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-10-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-11-20 | Reiterated | H.C. Wainwright | Buy |
| Oct-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Aug-20-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-13-20 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-28-20 | Upgrade | Wedbush | Neutral → Outperform |
| Feb-24-20 | Initiated | Jefferies | Buy |
| Feb-19-20 | Initiated | Stifel | Hold |
| Jan-27-20 | Upgrade | Goldman | Neutral → Buy |
| Sep-26-19 | Initiated | Wedbush | Neutral |
| Sep-13-19 | Initiated | Nomura | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
| Nov-15-18 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-12-18 | Initiated | Janney | Buy |
| Mar-12-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Jan-02-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Initiated | Goldman | Neutral |
| Jan-02-18 | Initiated | JP Morgan | Overweight |
| Jan-02-18 | Initiated | Morgan Stanley | Overweight |
View All
Denali Therapeutics Inc Stock (DNLI) Latest News
Will Denali's Expanding Pipeline Deliver Breakthroughs In Neurodegenerative Medicine? - RTTNews
Wedbush Maintains 'Outperform' Rating for DNLI, Lowers Price Tar - GuruFocus
Denali Therapeutics announces $200M proposed offering of common stock and pre-funded warrants - MSN
Denali Therapeutics dips after pricing $200M equity offering - MSN
Denali Therapeutics prices stock offering at $17.50 per share - MSN
Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment (DNLI) - Seeking Alpha
Denali Therapeutics (NASDAQ:DNLI) Shares Gap DownHere's What Happened - MarketBeat
Denali Therapeutics Prices $200 Million Public Offering - marketscreener.com
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - Sahm
Denali Therapeutics prices $200 million public offering By Investing.com - Investing.com India
Denali Therapeutics prices $200 million public offering - Investing.com
Denali Therapeutics says co prices public offering of 9.14 mln shares at $17.50 each - marketscreener.com
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire
Denali Therapeutics (NASDAQ: DNLI) prices $200M equity deal at $17.50 - Stock Titan
Denali Therapeutics slides after launching $200 million share sale - TradingView — Track All Markets
Denali Therapeutics Plans $200 Million Public Offering - marketscreener.com
Denali Therapeutics stock falls after announcing $200 million public offering By Investing.com - Investing.com Australia
Denali Therapeutics stock falls after announcing $200 million public offering - Investing.com
Denali Therapeutics announces $200 million public offering By Investing.com - Investing.com India
Denali Therapeutics announces $200 million public offering - Investing.com
Denali Therapeutics Inc. Announces $200 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Denali Therapeutics (NASDAQ: DNLI) plans $200M stock, pre-funded warrant sale with $30M option - Stock Titan
Marshall Wace LLP Sells 783,172 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Technical Reactions to DNLI Trends in Macro Strategies - news.stocktradersdaily.com
Denali enters into a $275M funding deal with Royalty Pharma - MSN
Denali clinches $275 million royalty deal to power potential breakthrough Hunter Syndrome therapy - Indian Pharma Post
Denali Therapeutics (DNLI): Rethinking Valuation After a 33% One-Month Share Price Rebound - Yahoo Finance
Denali’s Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI) - Yahoo Finance
BTIG Research Reiterates Buy Rating for Denali Therapeutics (NASDAQ:DNLI) - MarketBeat
3,947,387 Shares in Denali Therapeutics Inc. $DNLI Acquired by Norges Bank - MarketBeat
Denali Therapeutics stock maintains Buy rating at Stifel ahead of 2026 launch By Investing.com - Investing.com South Africa
Denali Therapeutics (MUN:4DN) Price Target Decreased by 15.88% to 28.11 - Nasdaq
What's Going On With Denali Therapeutics Stock Friday?Denali Therapeutics (NASDAQ:DNLI) - Benzinga
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
Denali Therapeutics stock maintains Buy rating at Stifel ahead of 2026 launch - Investing.com Nigeria
Wedbush Adjusts Denali Therapeutics Price Target to $31 From $30, Maintains Outperform Rating - marketscreener.com
FDA Pauses Denali’s Pompe Plans Due to Preclinical Safety Signals - BioSpace
BTIG Reiterates Denali Therapeutics (DNLI) Buy Recommendation - Nasdaq
William Blair Maintains Denali Therapeutics(DNLI.US) With Buy Rating - 富途牛牛
Schroder Investment Management Group Purchases 94,744 Shares of Denali Therapeutics Inc. $DNLI - MarketBeat
Denali Therapeutics stock rises on $275 million royalty deal with Royalty Pharma - Investing.com Australia
Transcript : Denali Therapeutics Inc.Analyst/Investor Day - MarketScreener
Denali Therapeutics and Royalty Pharma announce $275 million royalty funding agreement - marketscreener.com
Denali Therapeutics And Royalty Pharma Announce $275 Million Royalty Funding Agreement - TradingView
Denali Therapeutics and Royalty Pharma ink $275 million funding deal By Investing.com - Investing.com Nigeria
Denali Therapeutics and Royalty Pharma ink $275 million funding deal - Investing.com
Denali Therapeutics enters $275 million royalty funding agreement with Royalty Pharma - Investing.com
Denali Therapeutics secures $275M royalty funding deal - MSN
Denali Therapeutics Secures $275M Royalty Funding Deal - TipRanks
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Agreement for Tividenofusp Alfa Development - Quiver Quantitative
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement - The Manila Times
Denali Therapeutics Inc Stock (DNLI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):